Invivyd Inc
IVVD
NASDAQ
Biotechnology
$0.72
USD
+0.04 (+5.13%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $202.01M
Volume 2.0M
Revenue
$55.87M
TTM
+52.3%
YoY
Gross Margin
93%
TTM
-0.4%
YoY
Net Income
$-77.60M
TTM
+45.6%
YoY
Operating Cash Flow
$-78.72M
TTM
+44.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 11.3 | 11.8 | 13.1 | 17.2 | 13.7 |
YoY Growth | — | +420.6% | +41.2% | +24.5% | +21.6% |
Cost of Revenue | 0.8 | 0.7 | 1.1 | 1.1 | 1.0 |
Gross Profit | 10.5 | 11.1 | 12.0 | 16.1 | 12.7 |
Selling, General & Administrative | 16.8 | 16.6 | 15.0 | 18.6 | 25.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.4 | 26.2 | 23.1 | 28.6 | 55.8 |
Operating Income | -16.9 | -15.1 | -11.0 | -12.6 | -43.1 |
EBITDA | -16.6 | -14.9 | -10.9 | -12.4 | -43.0 |
Other Income / Expense | 0.6 | 0.4 | 0.6 | 1.5 | 1.7 |
Total Other Income / Expense | 0.6 | 0.4 | 0.6 | 1.5 | 1.7 |
Income Before Income Taxes | -16.3 | -14.7 | -10.5 | -11.1 | -41.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -16.3 | -14.7 | -10.5 | -11.1 | -41.4 |
Consolidated Net Income / Loss | -16.3 | -14.7 | -10.5 | -11.1 | -41.4 |
Net Income Attributable to Common Shareholders | -16.3 | -14.7 | -10.5 | -11.1 | -41.4 |
Basic EPS | -$0.14 | -$0.12 | -$0.06 | -$0.04 | -$0.13 |
Diluted EPS | -$0.14 | -$0.12 | -$0.06 | -$0.04 | -$0.13 |
Basic Shares Outstanding | 119.9M | 120.0M | 170.2M | 278.8M | 309.7M |
Diluted Shares Outstanding | 119.9M | 120.0M | 170.2M | 278.8M | 309.7M |